Drugs / WVE-004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05683860 | Dec 2022 → Jun 2023 | amyotrophic lateral sclerosis, frontotemporal dementia | Wave Life Sciences USA, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04931862 | Jun 2021 → Jun 2023 | amyotrophic lateral sclerosis, frontotemporal dementia | Wave Life Sciences USA, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WVE-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683860 ↗ |
| Modality | Antisense oligonucleotide | “stereopure antisense oligonucleotide (ASO)” NCT04931862 ↗ |
| Route | Intrathecal | “WVE-004 Administered Intrathecally” NCT04931862 ↗ |